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account for these changes in both conductance and gating. Such studies not
only expand our knowledge of the principal mechanisms underlying SF gating
of Kþ channels but may also help aid our understanding of how some Kþ
channel agonists exert their effects on the selectivity filter.
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Calcium ion elevations are required for human T-lymphocyte proliferation in
response to antigen recognition by a T-cell receptor. Calcium influx through
the plasma membrane is necessary for efficient T-cell proliferation and
effector function. The calcium channels responsible for Ca2þ influx in lymphocytes have been identified and Orai interacting with ER Ca2þ sensor
STIM were shown to be crucial for persistent calcium mobilization. Lossof-function mutations in Orai1 or STIM1 result in severe combined immunodeficiency (SCID) with muscle hypotonia. Suppression of calcium influx
through Orai/STIM channels gives rise to various lymphoproliferative defects.
Thus, deletion of Orai or STIM in mice results in lymphoproliferative disorders and hair loss. Gain-of-function mutations in Orai or STIM resulting in
constitutively activated channels cause tubular aggregate myopathy (TAM).
Despite the importance of Orai/STIM pathway in multiple signaling pathways
and diseases, small molecule high affinity specific inhibitors of these channels
are lacking. In this work we examined a class of indole-3-carboxamides for
their potential to inhibit store-operated Ca2þ entry. They were tested in vitro
for their ability to inhibit Orai1 mediated Ca2þ entry and currents. At 10 mM
and higher the less lipophilic BIC-154 was the most potent blocker in the
group. We used a constitutively active Orai1 variant implicated in TAM,
which does not require STIM1 for function. BIC-154 rapidly and reversibly
inhibited Orai1 currents. BTP2 (YM-58483) and 2-APB also inhibited
Orai1 mutant channels in the same cells. TRPM7, a Ca2þ/Mg2þ permeable
channel highly expressed in lymphocytes was insensitive to these compounds
tested at 100 mM. Future investigations will test their effectiveness in T-cell
blastogenesis and proliferation assays. We anticipate that Orai1-specific compounds will be useful for proof of concept studies of the contribution of this
channel to human disease.
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Cholesterol, a major membrane lipid component, has been known to modulate
the function of multiple ion channels by specific lipid-protein interactions, by
physical property changes of the membrane, or by modification of regulatory
proteins associated with the channels in signaling complexes. Previous studies
show that epithelial cells expressing the most common mutant version of the
Cystic Fibrosis Transmembrane conductance Regulator (CFTR), F508delCFTR, exhibit increased cholesterol content at the plasma membrane compared
to wild type control cells; however, neutrophils derived from CF patients show
reduced cholesterol levels in the plasma membrane. But whether cholesterol
directly modulates CFTR channel function remains unknown. To answer this
question, we combine heterologous expression in oocytes with more physiologically relevant Ussing chamber recordings utilizing polarized Fischer Rat Thyroid (FRT) cells to determine the effects of changing plasma membrane
cholesterol levels on CFTR channel function. Here, we report that cholesterol
depletion with methyl-b-cyclodextrin (MbCD) or cholesterol oxidase (CO) has
no macroscopic effect on the magnitude of CFTR-mediated whole-oocyte currents. However, depletion of cholesterol increased the effect of VX-770, a
clinically-used potentiator of CFTR, when channels were activated at high
PKA concentrations, but did not change the effect of VX-770 when channels
were activated at low PKA concentrations. This change in efficacy of VX770-mediated potentiation likely reflects the apparent shift in the sensitivity
of WT-CFTR to PKA after depletion of membrane cholesterol. In FRT cells,
P67L-CFTR also exhibited changes in phosphorylation-dependent activation
after depletion of plasma membrane cholesterol. Sensitivity of WT-CFTR to
block by GlyH-101 was significantly stronger after plasma membrane cholesterol depletion. These results demonstrate that changes in the cholesterol level
of the plasma membrane significantly modulate multiple CFTR channel func-
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tions. (Support: CF Fdn. MCCART17G0, NIH T32 GM008602, NIH F31
HL143863-01).
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There have been substantial advances in harnessing the immune system to fight
cancers using immunotherapies and engineered T cells. However, tumormediated immunosuppression represents a major obstacle to these approaches.
Dying necrotic cells in the tumour microenvironment release substantial
amount of intracellular potassium (Kþ), raising extracellular Kþ ([Kþ]e) to
25-60 mM. Tumor-infiltrating lymphocytes (TIL) bathed in this [Kþ]e-rich
fluid are suppressed by an ‘‘ionic-checkpoint’’ and fail to mount an efficient
antitumor response. Here, we demonstrate that T cells exposed to [Kþ]e-rich
media dose-dependently accumulate intracellular Kþ. Presence of high amount
of [Kþ]e (50 mM) resulted in significant suppression of T cell functions,
including proliferation, cytokine secretion, downstream signal transduction
(Akt and mTOR pathway) and tumor killing. To test if increased Kþ efflux
through Kþ channels would protect TILs from the suppressive effects of
high [Kþ]e, we patch-clamped TILs isolated from patients with metastatic colorectal cancer that were expanded ex vivo. We found them to express significant
numbers of calcium-activated KCa3.1 Kþ channels. Activators of KCa3.1 significantly enhanced KCa3.1 channel activity in both the cloned KCa3.1 and primary
T cells, rescued T cells from high [Kþ]e-induced suppression in cytokine and
tumor-killing. This study suggests that pharmacological activators of KCa3.1
enable T cells to overcome ionic-checkpoint-mediated immune suppression
and mount effective antitumor activity.
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Liver fibrosis resulting from non-alcoholic fatty liver disease (NAFLD) is a
leading cause of liver-related morbidity and mortality. Thecalcium-activatedKCa3.1 potassium channel is considered a therapeutic target for this disease
because of its role in myofibroblasts and T cells, which are key drivers of
fibrosis. Here, we describe the development of novel KCa3.1 inhibitors. Our
starting template nifedipine, a dihydropyridine, blocks KCa3.1 with an IC50 =
1.8 mM. Nifedipine analogues were screened for blocking of KCa3.1 using automated planar electrophysiology. Structure-activity-relationship analysis led to
the identification of novel analogues with IC50 in the low nanomolar range.
Mutagenesis studies showed that Nifedipine bound to the fenestration region
of KCa3.1, while the new analogues bound in the channel pore. Molecular
modeling and simulations were used to characterize the binding of these compounds. In parallel, we tested KCa3.1 inhibitor TRAM-34 in mice reconstituted
with a functional human immune system and fed an obesity-inducing diet.
TRAM-34 prevented the progression of NALFD to liver fibrosis, reduced T
cell infiltration of the liver and reduced circulating levels of IFN-g and IL17. These studies indicate that KCa3.1 blockers may have use in the treatment
of diet-induced liver fibrosis.
1236-Pos
Structural Modeling of Drug Interactions with hERG Channel in Open
and Closed States
Aiyana M. Emigh1,2, Kevin R. DeMarco1, Kazuharu Furutani1, Jon T. Sack1,
Colleen E. Clancy1, Igor V. Vorobyov1, Vladimir Yarov-Yarovoy1.
1
Physiology & Membrane Biology, Univ Calif Davis, Davis, CA, USA,
2
Biophysics Graduate Group, Univ Calif Davis, Davis, CA, USA.

